REGENXBIO, Inc. (RGNX)
7.78
-0.48
(-5.81%)
USD |
NASDAQ |
Mar 27, 16:00
7.58
-0.20
(-2.57%)
After-Hours: 17:21
REGENXBIO Cash from Investing (Quarterly) : 37.54M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 96.21M |
| AbbVie, Inc. | -1.463B |
| Krystal Biotech, Inc. | 11.16M |
| Replimune Group, Inc. | 75.12M |
| Ocugen, Inc. | -0.035M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -52.29M |
| Cash from Financing (Quarterly) | -9.584M |
| Free Cash Flow | -126.38M |
| Free Cash Flow Per Share (Quarterly) | -1.020 |
| Free Cash Flow to Equity (Quarterly) | -45.18M |
| Free Cash Flow to Firm (Quarterly) | -40.52M |
| Free Cash Flow Yield | -31.49% |